Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure

Elli̇dağ, Hamit Yaşar; Eren, Esin; Yılmaz, Necat; Çekın, Yeşim

doi:10.1179/1351000213y.0000000083

Cited by 42 publications

(36 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ischemia modified albumin (IMA) test does predict early about the cardiac ischemia. [14][15][16] and is a good prognostic marker in chronic ischemic heart failure 16 and Coronary artery bypass graft surgery (CABG). 17 This is positive in a variety of conditions giving rise to tissue ischemia.…”

Section: Methodsmentioning

confidence: 99%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

Aims and Objectives: To find out if ischemia modified albumin can be a novel marker in ischemic heart disease. Materials and methods: Retrospective chart-review of chest pain patients who were evaluated in the emergency departments in 2006 and 2007. Results: Total of 400 patients presented with chest pain and subsequently were evaluated in the Emergency department at two major emergency departments associated with the teaching hospital associated Mercy Catholic Medical Center; few patients were excluded due to unavailability of complete data and follow-up visit in next six months. Thus, finally 351 patients met criteria for final analysis. Primary endpoints included the cardiac events and secondary outcomes were course in the hospital, days of hospitalization, interventions done in the hospital, disposition from the hospital, and readmission within next six months. Sensitivity and specificity of ischemia modified albumin (IMA) test was 80% and 50% respectively and positive predictive value and negative predictive values were 17% and 88% respectively. There were no further differences in cardiac events or interventions in higher ischemia modified albumin (IMA) group as compared to troponin (cTnT) (p=0.5). People with higher ischemia modified albumin (IMA) showed longer hospitalization days (p=0.025), needing nursing home or skilled nursing facility on discharge due to high discharge needs (p=0.0001) and had more readmissions as compared to troponin (p=0.02). However, Higher ischemia modified albumin (IMA) did not predict more cardiovascular events during hospital stay, rather troponin (cTnT) test predicted arrhythmia more than ischemia modified albumin (IMA) test (p=0.0001). Conclusion: Ischemia-modified albumin may be utilized as a novel marker of ischemia to rule out acute coronary syndrome along with troponin and electrocardiogram in the emergency departments. This test may also have short and long-term prognostic significances and may even be used as a surrogate marker in stroke, sepsis and thrombo-embolic diseases once these people need admission to the hospital.

show abstract

Section: Methodsmentioning

confidence: 99%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

show abstract

“…Based on the currently available literature, a majority of the HF conditions have been correlated with oxidative stress for the past several decades. In particular, ischemic heart disease and/or reperfusion injury have been shown to display a hyper-oxidative state wherein increased reactive oxygen and nitrogen species (ROS/RNS) generation correlates with a worsening of myocardial injury [9][10][11]. In spite of these observations, supplementation with antioxidants seems to be inefficient to treat such conditions in a failing heart [12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Evidence for a hyper-reductive redox in a sub-set of heart failure patients

Sairam

Patel

Subrahmanian

et al. 2018

Preprint

View full text Add to dashboard Cite

show abstract

“…Decreases in antioxidant enzymes, such as superoxide dismutase (SOD) and the elevated presence of DNA and lipid oxidation have also been reported [4,10,[13][14][15][16]. While these studies have provided valuable insight into the role of oxidative stress in congestive heart failure (CHF), they did not account for possible differences between the sexes.…”

Section: Introductionmentioning

confidence: 99%

“…The presence of oxidative stress in heart failure has been identified by the increased generation of ROS via increased NADPH oxidase (NOX), xanthine oxidase, myeloperoxidase (MPO), and other pro-oxidant enzyme activities [4,[6][7][8][9][10][11][12], leading to specific foot-prints of oxidative damage. Decreases in antioxidant enzymes, such as superoxide dismutase (SOD) and the elevated presence of DNA and lipid oxidation have also been reported [4,10,[13][14][15][16].…”

Section: Introductionmentioning

confidence: 99%

“…The pathological generation of these pro-oxidants can lead to a state of oxidative stress, defined most recently by Sies in his review of oxidative stress, as 'An imbalance between oxidants and anti-oxidants in favor of the oxidants, leading to a disruption of redox signaling and control and/or molecular damage' [3]. Oxidative stress in cardiovascular disease has been implicated in vascular inflammation, impaired endothelial function and vascular tone, cardiomyocyte apoptosis, and ultimately heart failure [2,4,5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Poor acute outcome in congestive heart failure is associated with increases in the plasma static oxidation–reduction potentials (sORP) in men but not in women

et al. 2017

View full text Add to dashboard Cite

Objectives: In congestive heart failure (CHF), men are younger, more likely to have reduced ejection fraction (HF-rEF), and to be diabetic compared to women. Despite this, sex differences in oxidative stress have yet to be explored in CHF. Methods: Data from 67 males and 63 females hospitalized for CHF were collected. Static oxidationreduction potential (sORP), a relative indicator of oxidative stress, and capacity ORP (icORP), a relative indicator of antioxidant capacity, were measured from plasma samples. We examined whether sex modified the relationship between ORP and hospital discharge disposition (poor outcome: death, hospice), along with other demographics, medications, and diagnostic parameters. Results: Males with poor outcomes had higher sORP and icORP values than females (P < 0.05). For those with a good outcome, there were no differences between the sexes (P > 0.05). Males were younger and more likely to have HF-rEF and diabetes. Controlling for these variables did not account for the sex differences in ORP measures. Regardless of sex, higher creatinine was related to higher sORP and icORP, while lower magnesium and potassium were related to higher sORP and icORP, respectively. Discussion: Increases in sORP during CHF are partially affected by sex and acute outcomes, but are also related to variables without sexual biases.

show abstract

Oxidative stress and ischemia-modified albumin in chronic ischemic heart failure

Abstract: We observed impaired oxidant/antioxidant status in favor of oxidative stress in CIHF patients. Oxidative stress may be a key factor in the development of hypoalbuminemia in CIHF. Further studies are needed to establish the relationships among IMA, albumin, and redox balance in CIHF.

Cited by 42 publications

References 34 publications

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Evidence for a hyper-reductive redox in a sub-set of heart failure patients

Poor acute outcome in congestive heart failure is associated with increases in the plasma static oxidation–reduction potentials (sORP) in men but not in women

Contact Info

Product

Resources

About